Chapter 4 Market and Technology Background
- Overview of Biomarkers
- Classification of Biomarkers
- Types of Biomarkers
- Biomarker Discovery, Verification and Validation
- Overview of Cancer
- Cancer/Oncology Biomarkers
- Oncology Biomarkers Testing Methods
- Oncology Biomarkers Testing Types
- Biomarker Test Development and Marketing
Chapter 5 Market Dynamics
- Drivers
- Rising Incidence of Cancer
- Increasing Use of Biomarkers in Drug Discovery and Development
- Developments in Analytical Technologies and Assay Methods
- Increased Availability and Ease of Biomarker Testing
- Support from Regulatory Agencies
- Barriers
- Inadequate Patient Access to and Insurance Coverage of Biomarker Testing
- Technical Errors and Delayed Test Results
- Low Provider and Patient Awareness
- Suboptimal Tissue Procurement and Triaging
- Shortages of Laboratories and Personnel
Chapter 6 Market Breakdown by Biomarker Type
- Protein Biomarkers
- Protein Biomarkers Profiling Technologies
- Genomic Biomarker
- Genomic Biomarkers Profiling Technologies
- Other Biomarkers
- Metabolomic Biomarkers
- Cellular Biomarkers
- Global Market for Oncology Biomarkers, by Biomarker Type
- Protein Biomarkers
- Genomic Biomarkers
- Other Biomarkers
Chapter 7 Market Breakdown by Application
- Life Science Research
- Risk Assessment and Screening
- Diagnostics
- Prognostics
- Therapeutic Selection and Clinical Trials
- Monitoring
- Response Monitoring
- Recurrence/Minimal Residual Disease (MRD) Monitoring
- Global Market for Oncology Biomarkers by Application
- Life Science Research
- Risk Assessment and Screening
- Diagnostics
- Prognostics
- Therapeutic Selection and Clinical Trials
- Monitoring
Chapter 8 Market Breakdown by Cancer Type
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer (CRC)
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Leukemia
- Others
- Ovarian Cancer
- Liver Cancer
- Thyroid Cancer
- Cervical Cancer
- Kidney Cancer
- Endometrial Cancer
- Global Market for Oncology Biomarkers by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Leukemia
- Other Cancers
Chapter 9 Market Breakdown by Region
- Global Market for Oncology Biomarkers by Region
- North America
- Market Revenue by Application
- Market Revenue by Country
- Europe
- Market Revenue by Application
- Market Revenue by Country
- Asia-Pacific
- Market Revenue by Application
- Market Revenue by Country
- Rest of World
- Market Revenue by Application
Chapter 10 Impact of COVID-19
- Overview
- Implications on Cancer Diagnosis
- Implications on Cancer Treatment
- Impact on Oncology Biomarkers Market
Chapter 11 Emerging Trends and Technologies in the Market
- Emerging Technologies and Trends in the Market
- Liquid Biopsy
- Circulating Free Nucleic Acids
- Circulating Cell-Free DNA (CfDNA)
- “Organ Agnostic” Biomarker Testing
- PD-L1
- Homologous Recombination De?ciency (HRD)
- Blood Test for Early-Stage Cancer Detection
Chapter 12 Competitive Landscape
- Overview
- Mergers and Acquisitions
- SWOT Analysis for Global Oncology Biomarker Market
- Porter’s Five Forces Analysis of Global Oncology Biomarker Market
Chapter 13 Company Profiles
- AGENDIA INC.
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BIOCARTIS NV
- BIOMERIEUX S.A.
- BIO-RAD LABORATORIES INC.
- BECTON, DICKINSON & CO.
- EXACT SCIENCES CORP.
- F. HOFFMANN-LA ROCHE AG
- GUARDANT HEALTH INC.
- HOLOGIC INC.
- ILLUMINA INC.
- LEICA BIOSYSTEMS
- MERCK KGAA
- MYRIAD GENETICS INC.
- QIAGEN N.V.
- SIEMENS HEALTHINEERS AG
- THERMO FISHER SCIENTIFIC INC.
- VERACYTE INC.
List of Tables
Summary Table: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 1: Different Categories of Biomarkers
Table 2: Multiple Paths to Market for Biomarker Test
Table 3: Biomarkers: Drug Development
Table 4: FDA Issued Letters of Support to Cancer Biomarkers
Table 5: Three Biggest Barriers to Biomarker Testing
Table 6: Selected Protein Biomarkers Used in Oncology
Table 7: Examples of Genomic Biomarkers
Table 8: NGS Methods Used in Oncology
Table 9: PMA Approved NGS Oncology Panel, Somatic or Germline Variant Detection System
Table 10: Selected Genomic Biomarkers Used in Oncology
Table 11: Potential Applications of CTC-Based Diagnostics
Table 12: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 13: FDA Novel Drug Approvals with Predictive Biomarkers, Jan. 2021-Jan. 2023
Table 14: Total Number of Biomarkers Used in FDA Approved Therapeutic Selection Tests or CDx, by Cancer Type, 2022
Table 15: Global Market for Oncology Biomarkers, by Application, Through 2028
Table 16: NIH Funding for Cancer Research, by Cancer Type, Through 2024
Table 17: Total Number of Drugs with Approved CDx, by Cancer Type, 2021
Table 18: Estimated Numbers for All Cancers Excl. Non-Melanoma Skin Cancer in 2020
Table 19: Selected Key Biomarkers for Breast Cancer
Table 20: Biomarkers Used in Breast Cancer Therapy Selection
Table 21: Selected Key Biomarkers for Lung Cancer
Table 22: Biomarkers Used in Lung Cancer Therapy Selection
Table 23: Selected CRC Screening Products/Tests
Table 24: Selected Key Biomarkers for CRC
Table 25: Biomarkers Used in CRC Therapy Selection
Table 26: Selected Prostate Cancer Screening Tests
Table 27: Biomarkers Used in Prostrate Cancer Therapy Selection
Table 28: Selected Key Biomarkers for Prostate Cancer
Table 29: Selected Key Biomarkers for Bladder Cancer
Table 30: Biomarkers Used in Bladder Cancer Therapy Selection
Table 31: Selected Key Biomarkers for Melanoma
Table 32: Biomarkers Used in Melanoma Therapy Selection
Table 33: Selected Key Biomarkers for Leukemia
Table 34: Biomarkers Used in Leukemia Therapy Selection
Table 35: Selected Key Biomarkers for Ovarian Cancer
Table 36: Biomarkers Used in Ovarian Cancer Therapy Selection
Table 37: Global Market for Oncology Biomarkers, by Cancer Type, Through 2028
Table 38: Global Market for Breast Cancer Biomarkers, by Biomarker Type, Through 2028
Table 39: Global Market for Lung Biomarkers, by Biomarker Type, Through 2028
Table 40: Global Market for Colorectal Cancer Biomarkers, by Biomarker Type, Through 2028
Table 41: Global Market for Prostate Cancer Biomarkers, by Biomarker Type, Through 2028
Table 42: Global Market for Bladder Cancer Biomarkers, by Biomarker Type, Through 2028
Table 43: Global Market for Melanoma Biomarkers, by Biomarker Type, Through 2028
Table 44: Global Market for Leukemia Biomarkers, by Biomarker Type, Through 2028
Table 45: Global Market for Other Cancers Biomarkers, by Biomarker Type, Through 2028
Table 46: Global Market for Oncology Biomarkers, by Region, Through 2028
Table 47: Estimated Numbers of New Cases and Deaths for Common Cancer Type in the U.S. in 2023
Table 48: North American Market for Oncology Biomarkers, by Application, Through 2028
Table 49: North American Market for Oncology Biomarkers, by Country, Through 2028
Table 50: Challenges to Biomarker Testing in Europe
Table 51: Demographic, Cancer and Healthcare Statistics for Selected European Countries
Table 52: Estimated Cancer Incidence and Mortality, Age Standardized Rate in the EU Countries, by Cancer Type, 2020
Table 53: European Market for Oncology Biomarkers, by Application, Through 2028
Table 54: European Market for Oncology Biomarkers, by Country, Through 2028
Table 55: Oncology Statistics in Select Asia-Pacific Countries, 2020
Table 56: Estimated Cancer Cases in Asia-Pacific Countries, by Notable Cancer Types, 2020
Table 57: Asia-Pacific Market for Oncology Biomarkers, by Application, Through 2028
Table 58: Asia-Pacific Market for Oncology Biomarkers, by Country, Through 2028
Table 59: Cancer Statistics, South America and Africa, 2020
Table 60: RoW Market for Oncology Biomarkers, by Application, Through 2028
Table 61: Selected CfDNA-Based Cancer Tests
Table 62: Leading Market Players in Oncology Biomarkers Market, 2022
Table 63: Recent Mergers and Acquisitions in Oncology Biomarkers Market, 2020-2022
Table 64: Porter’s Five Forces Analysis: Global Oncology Biomarkers Market
Table 65: Agilent Technologies Inc.: Selected Key Developments, January 2021-March 2023
Table 66: Biocartis: Selected Key Developments, January 2020-March 2023
Table 67: Bio-Rad Laboratories: Selected Key Developments, January 2020-March 2023
Table 68: BD: Business Segments
Table 69: BD: Selected Key Developments, January 2020-March 2023
Table 70: Exact Sciences Corp.: Key Developments, January 2021 to December 2022
Table 71: Roche: Selected Recent Developments, January 2021 to March 2023
Table 72: Guardant Health: Key Developments, 2021-2022
Table 73: Hologic Inc.: Key Developments, January 2021 to December 2022
Table 74: Illumina Inc: Key Developments, 2021 and 2022
Table 75: Leica Biosystems: Key Developments, January 2021 to December 2022
Table 76: Myriad Genetics: Key Developments, January 2021 to December 2022
Table 77: Qiagen: Key Recent Developments, 2021-April 2023
Table 78: Thermo Fisher Scientific Inc.: Key Developments, January 2021 to January 2023
Table 79: Veracyte: Key Recent Developments, Jan 2021-Jan 2023
Table 80: Abbreviations Used in This Report
List of Figures
Summary Figure: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 1: Biomarker Types Categorized by Application and Use in Drug Development and Disease Management
Figure 2: Molecular and Imaging Biomarkers
Figure 3: Biomarker Discovery, Verification and Validation
Figure 4: Cancer Care Spectrum
Figure 5: Types of Biomarker Testing and Their Definitions
Figure 6: Biomarkers in Personalized Treatment
Figure 7: Global Cancer Incidence, by Region, 2020
Figure 8: Global Cancer Incidence, by Region, 2020 vs. 2040
Figure 9: Distribution Shares of R&D Investment in Drug Development, by Function, 2020
Figure 10: Overview of Biomarker Test Benefits for Each Stakeholder
Figure 11: Barriers to the Use of Biomarker Tests Throughout the Patient Journey
Figure 12: Top Barriers to Biomarker Testing in the U.S., 2021
Figure 13: Common Biomarker Testing Methodologies
Figure 14: Four Main Classes of Genomic Alterations
Figure 15: Types of Genomic Biomarkers
Figure 16: Genomic Biomarker Testing Methods
Figure 17: Key Advantages of NGS for Precision Oncology Applications
Figure 18: Evolution of Biomarkers in Clinical Practice
Figure 19: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 20: Global Market Shares of Oncology Biomarkers, by Biomarker Type, 2022
Figure 21: Hallmark of Cancer
Figure 22: Stages of Cancer
Figure 23: Companion Diagnostics Co-Development Process from Biomarker Discovery to Regulatory Approval
Figure 24: Clinical Applications of Biomarkers in Oncology
Figure 25: Global Market for Oncology Biomarkers, by Application, 2020-2028
Figure 26: Global Market Shares of Oncology Biomarkers, by Application, 2022
Figure 27: Five-Year Overall Survival Rates in the U.S., by Cancer Type
Figure 28: Global Market for Oncology Biomarkers, by Cancer Type, 2020-2028
Figure 29: Global Market Shares of Oncology Biomarkers, by Cancer Type, 2022
Figure 30: Global Market Shares of Breast Cancer Biomarkers, by Biomarker Type, 2022
Figure 31: Global Market Shares of Lung Biomarkers, by Biomarker Type, 2022
Figure 32: Global Market Shares of Colorectal Cancer Biomarkers, by Biomarker Type, 2022
Figure 33: Global Market Shares of Prostate Cancer Biomarkers, by Biomarker Type, 2022
Figure 34: Global Market Shares of Bladder Cancer Biomarkers, by Biomarker Type, 2022
Figure 35: Global Market Shares of Melanoma Biomarkers, by Biomarker Type, 2022
Figure 36: Global Market Shares of Leukemia Biomarkers, by Biomarker Type, 2022
Figure 37: Global Market Shares of Other Cancers Biomarkers, by Biomarker Type, 2022
Figure 38: Global Market for Oncology Biomarkers, by Region, 2020-2028
Figure 39: Global Market Shares of Oncology Biomarkers, by Region, 2022
Figure 40: NIH's Cancer and Cancer Genomics Research Funding, by Year, 2018-2024
Figure 41: North American Market Shares of Oncology Biomarkers, by Application, 2022
Figure 42: European Market Shares of Oncology Biomarkers, by Application, 2022
Figure 43: Asia-Pacific Market Shares of Oncology Biomarkers, by Application, 2022
Figure 44: RoW Market Shares of Oncology Biomarkers, by Application, 2022
Figure 45: Emerging Trends/Technologies in the Oncology Biomarkers Market
Figure 46: Advantages of Liquid Biopsy
Figure 47: PubMed Article Count: “Liquid Biopsy”, 2014-2022
Figure 48: Pan-Cancer Genomic Biomarkers
Figure 49: SWOT Analysis of the Global Oncology Biomarkers Market
Figure 50: Abbott: Diagnostics Revenue, 2020-2022
Figure 51: Abbott: Diagnostics Market Share, by Business Segment, 2022
Figure 52: Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2020-2022
Figure 53: Biocartis: Annual Net Revenue, 2020-2022
Figure 54: Biocartis: Market Share, by Business Segment, 2022
Figure 55: BioMérieux SA: Annual Net Revenue, 2020-2022
Figure 56: BioMérieux SA: Market Share, by Application, 2022
Figure 57: Bio-Rad Laboratories: Annual Net Revenue, 2020-2022
Figure 58: Bio-Rad Laboratories: Market Share, by Business Segment, 2022
Figure 59: BD’s Biosciences Segment: Annual Revenue, 2020-2022
Figure 60: Exact Sciences Corp.: Annual Net Revenue, 2020-2022
Figure 61: Exact Sciences Corp.: Market Share, by Business Segment, 2022
Figure 62: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Annual Revenue, 2020-2022
Figure 63: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Market Share, by Customer Area, 2022
Figure 64: Guardant Health: Annual Net Revenue, 2020-2022
Figure 65: Guardant Health: Market Share, by Segment, 2022
Figure 66: Hologic Inc.: Annual Net Revenue, 2020-2022
Figure 67: Hologic Inc.: Market Share, by Business Segment, 2022
Figure 68: Illumina Inc.: Annual Net Revenue, 2020-2022
Figure 69: Illumina Inc.: Market Share, by Business Segment, 2022
Figure 70: Merck KGaA: Annual Revenue, 2020-2022
Figure 71: Merck KGaA: Market Share, by Business Segment, 2022
Figure 72: Myriad Genetics: Annual Net Revenue, 2021 and 2022
Figure 73: Myriad Genetics: Market Share, by Business Segment, 2022
Figure 74: Qiagen: Annual Net Revenue, 2020-2022
Figure 75: Qiagen: Market Share, by Product Type, 2022
Figure 76: Siemens Healthineers AG: Annual Net Revenue, 2020-2022
Figure 77: Siemens Healthineers AG: Market Share, by Business Segment, 2022
Figure 78: Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022
Figure 79: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022
Figure 80: Veracyte: Annual Revenue, 2020-2022
Figure 81: Veracyte: Market Share, by Business Segment, 2022
